Research progress of biological functions of miR-101-3p in cardiovascular diseases

doi:10.11958/20252447

Abstract

Abstract:

miR-101-3p is an evolutionarily conserved non-coding RNA that has shown aberrant expression and regulatory functios in various cardiovascular diseases (CVDs) in recent years. It participates in key pathological processes including post-infarction myocardial remodeling, myocardial fibrosis in heart failure and the development of atherosclerosis by modulating pathways such as apoptosis, autophagy and metabolism. In addition, it exhibits immunoregulatory potential in myocardium injury related to systemic diseases. This review summarizes the recent advances in understanding the role of miR-101-3p in CVDs, focusing on its expression dynamics and regulatory mechanisms in different disease models. It further elaborates on the biological effects of miR-101-3p in cardiovascular pathology and explores its potential as a diagnostic biomarker and therapeutic target. miR-101-3p is expected to provide novel insights for early detection and targeted intervention of cardiovascular diseases.

Key words: myocardial infarction, heart failure, atherosclerosis, miR-101-3p, myocardial fibrosis

CLC Number:

R541.4

References 42

[1]	CHONG B, JAYABASKARAN J, JAUHARI S M, et al. Global burden of cardiovascular diseases:projections from 2025 to 2050[J]. Eur J Prev Cardiol, 2025, 32(11):1001-1015. doi:10.1093/eurjpc/zwae281.
[2]	CIPRIANO G L, SCHEPICI G, MAZZON E, et al. Multiple sclerosis:Roles of miRNA,lcnRNA,and circRNA and their implications in cellular pathways[J]. Int J Mol Sci, 2024, 25(4):2255. doi:10.3390/ijms25042255.
[3]	吴宾, 杨自更, 金玲, 等. miRNA-381-3p/MuRF1轴对低氧性肺动脉高压小鼠心肺损伤的影响[J]. 天津医药, 2025, 53(6):571-577.
	WU B, YANG Z G, JIN L, et al. Effect of miRNA-381-3p/MuRF1 axis on cardiopulmonary injury in mice with hypoxic pulmonary hypertension[J]. Tianjin Med J, 2025, 53(6):571-577. doi:10.11958/20251127.
[4]	PONTEMEZZO E, FOGLIO E, VERNUCCI E, et al. miR-200c-3p regulates epitelial-to-mesenchymal transition in epicardial mesothelial cells by targeting epicardial follistatin-related protein 1[J]. Int J Mol Sci, 2021, 22(9):4971. doi:10.3390/ijms22094971.
[5]	DUEÑAS A, EXPÓSITO A, MUÑOZ M, et al. MiR-195 enhances cardiomyogenic differentiation of the proepicardium/septum transversum by Smurf1 and Foxp1 modulation[J]. Sci Rep, 2020, 10(1):9334. doi:10.1038/s41598-020-66325-x.
[6]	KHIDR E G, ABULSOUD A I, DOGHISH A A, et al. The potential role of miRNAs in the pathogenesis of cardiovascular diseases - A focus on signaling pathways interplay[J]. Pathol Res Pract, 2023, 248:154624. doi:10.1016/j.prp.2023.154624.
[7]	XIN Y, TANG L, CHEN J, et al. Inhibition of miR-101-3p protects against sepsis-induced myocardial injury by inhibiting MAPK and NF-κB pathway activation via the upregulation of DUSP1[J]. Int J Mol Med, 2021, 47(3):20. doi:10.3892/ijmm.2021.4853.
[8]	GRIFFITHS-JONES S, GROCOCK R J, VAN DONGEN S, et al. miRBase:microRNA sequences,targets and gene nomenclature[J]. Nucleic Acids Res, 2006, 34(Database issue):D140-144. doi:10.1093/nar/gkj112.
[9]	LIU N, YANG C, GAO A, et al. MiR-101: An important regulator of gene expression and tumor ecosystem[J]. Cancers(Basel), 2022, 14(23):5861. doi:10.3390/cancers14235861.
[10]	GUO X, CHEN M, CAO L, et al. Cancer-associated fibroblasts promote migration and invasion of non-small cell lung cancer cells via miR-101-3p mediated VEGFA secretion and AKT/eNOS pathway[J]. Frontiers in cell and developmental biology, 2021, 9:764151. doi:10.3389/fcell.2021.764151.
[11]	WANG J, ZHANG W, ZHANG R, et al. MiR-101-3p promotes tumor cell proliferation and migration via the wnt signal pathway in MNNG-induced esophageal squamous cell carcinoma[J]. Toxics, 2024, 12(11):824. doi:10.3390/toxics12110824.
[12]	LIU M, GAO H, HE Y, et al. Upregulation of miR-101-3p overcomes ibrutinib resistance by targeting ABCC5 in diffuse large B-cell lymphoma(DLBCL)[J]. Journal of Hard Tissue Biology, 2023, 32(1):11-20. doi:10.2485/jhtb.32.11.
[13]	WANG H, WANG L, ZHANG G, et al. MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer[J]. Oncotarget, 2018, 9(7):7501-7512. doi:10.18632/oncotarget.23483.
[14]	BAKHSHI A, KHANI M, ALIPOUR PARSA S, et al. Investigating the expression level of miR-17-3p,miR-101-3p,miR-335-3p,and miR-296-3p in the peripheral blood of patients with acute myocardial infarction[J]. Mol Cell Biochem, 2024, 479(4):859-868. doi:10.1007/s11010-023-04766-4.
[15]	WANG J, YANG X, LI R, et al. LncRNA SNHG6 inhibits apoptosis by regulating EZH2 expression via the sponging of miR-101-3p in esophageal squamous-cell carcinoma[J]. Onco Targets Ther, 2020, 13:11411-11420. doi:10.2147/OTT.S275135.
[16]	ABDI J, RASTGOO N, CHEN Y, et al. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells[J]. BMC Cancer, 2019, 19(1):975. doi:10.1186/s12885-019-6151-x.
[17]	ZHU W, NI Q, WANG Z, et al. MiR-101-3p targets the PI3K-AKT signaling pathway via Birc5 to inhibit invasion,proliferation,and epithelial-mesenchymal transition in hepatocellular carcinoma[J]. Clin Exp Med, 2025, 25(1):88. doi:10.1007/s10238-025-01622-1.
[18]	SUN H, ZHU R, GUO X, et al. Exosome miR-101-3p derived from bone marrow mesenchymal stem cells promotes radiotherapy sensitivity in non-small cell lung cancer by regulating DNA damage repair and autophagy levels through EZH2[J]. Pathol Res Pract, 2024, 256:155271. doi:10.1016/j.prp.2024.155271.
[19]	PARK J, CHO M, CHO J, et al. MicroRNA-101-3p suppresses cancer cell growth by inhibiting the USP47-induced deubiquitination of RPL11[J]. Cancers(Basel), 2022, 14(4):964. doi:10.3390/cancers14040964.
[20]	TAO L, XU C, SHEN W, et al. HIPK3 inhibition by exosomal hsa-miR-101-3p is related to metabolic reprogramming in colorectal cancer[J]. Front Oncol, 2021, 11:758336. doi:10.3389/fonc.2021.758336.
[21]	ZIEMANN M, LIM S C, KANG Y, et al. MicroRNA-101-3p modulates mitochondrial metabolism via the regulation of complex II assembly[J]. J Mol Biol, 2022, 434(2):167361. doi:10.1016/j.jmb.2021.167361.
[22]	HUA G, ZENG Z L, SHI Y T, et al. LncRNA XIST contributes to cisplatin resistance of lung cancer cells by promoting cellular glycolysis through sponging miR-101-3p[J]. Pharmacology, 2021, 106(9/10):498-508. doi:10.1159/000512621.
[23]	XU C F, CAO Q, ZHANG B F. Catalpol improves insulin resistance and lipid metabolism disorder in diabetic mice by inhibiting microRNA-101-3p to up-regulate FOS-related antigen 2[J]. J Physiol Pharmacol, 2024, 75(3). doi:10.26402/jpp.2024.3.05. [Epub 2024 Jul 18]
[24]	MAHMOUDIAN ESFAHANI M, MOSTASHFI M, VAHEB HOSSEINABADI S, et al. Unveiling the regulatory of miR-101-3p on ZNF746 in a Parkinson's disease cell model:Implications for therapeutic targeting[J]. Neurosci Res, 2024, 203:18-27. doi:10.1016/j.neures.2023.12.001.
[25]	ZHANG T, ZHAO S, GU C. Role of PGC-1α in the proliferation and metastasis of malignant tumors[J]. J Mol Histol, 2025, 56(2):77. doi:10.1007/s10735-025-10360-3.
[26]	ZHANG Y, WANG Y, ZHAO F. Application of the trend of miRNA expression levels in APP/PS1 mice plasma for the early diagnosis of Alzheimer's disease[J]. Mol Neurobiol, 2025, 62(6):7792-7804. doi:10.1007/s12035-025-04743-6.
[27]	SONG L, FENG S, YU H, et al. Dexmedetomidine protects against kidney fibrosis in diabetic mice by targeting miR-101-3p-mediated EndMT[J]. Dose Response, 2022, 20(1):15593258221083486. doi:10.1177/15593258221083486.
[28]	ZHANG J, XU X, WANG M. Clinical significance of serum miR-101-3p expression in patients with neonatal sepsis[J]. Per Med, 2021, 18(6):541-550. doi:10.2217/pme-2020-0182.
[29]	ZHAO X, LI S, WANG Z, et al. miR-101-3p negatively regulates inflammation in systemic lupus erythematosus via MAPK1 targeting and inhibition of the NF-κB pathway[J]. Mol Med Rep, 2021, 23(5):359. doi:10.3892/mmr.2021.11998.
[30]	CHEN Q, LI X, KONG L, et al. miR-101-3p induces vascular endothelial cell dysfunction by targeting tet methylcytosine dioxygenase 2[J]. Acta Biochim Biophys Sin(Shanghai), 2020, 52(2):180-191. doi:10.1093/abbs/gmz154.
[31]	谢田田, 赵春虎, 袁文生, 等. 老年急性ST段抬高型心肌梗死患者血清lnc-MALAT1、miR-101-3p水平与心功能分级及短期预后的相关性[J]. 中国老年学杂志, 2024, 44(16):3841-3844.
	XIE T T, ZHAO C H, YUAN W S, et al. Correlation between serum lnc-MALAT1 and miR-101-3p levels and cardiac function classification and short-term prognosis in elderly patients with acute ST-segment elevation myocardial infarction[J]. Chinese Journal of Gerontology, 2024, 44(16):3841-3844. doi:10.3969/j.issn.1005-9202.2024.16.001.
[32]	SANTOS-FARIA J, GAVINA C, RODRIGUES P, et al. MicroRNAs and ventricular remodeling in aortic stenosis[J]. Rev Port Cardiol(Engl Ed), 2020, 39(7):377-387. doi:10.1016/j.repc.2019.09.014.
[33]	CHEN J, LIN Y, SUN Z. Inhibition of miR-101-3p prevents human aortic valve interstitial cell calcification through regulation of CDH11/SOX9 expression[J]. Mol Med, 2023, 29(1):24. doi:10.1186/s10020-023-00619-4.
[34]	WAN F, MA X, WANG J, et al. Evaluation of left ventricular dysfunction by three-dimensional speckle-tracking echocardiography and bioinformatics analysis of circulating exosomal miRNA in obese patients[J]. BMC Cardiovasc Disord, 2023, 23(1):450. doi:10.1186/s12872-023-03502-6.
[35]	PAN Z, SUN X, SHAN H, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway[J]. Circulation, 2012, 126(7):840-850. doi:10.1161/CIRCULATIONAHA.112.094524.
[36]	CHENG S, ZHOU F, XU Y, et al. Geniposide regulates the miR-101/MKP-1/p38 pathway and alleviates atherosclerosis inflammatory injury in ApoE-/- mice[J]. Immunobiology, 2019, 224(2):296-306. doi:10.1016/j.imbio.2018.12.005.
[37]	TAN W H, PENG Z L, YOU T, et al. CTRP15 promotes macrophage cholesterol efflux and attenuates atherosclerosis by increasing the expression of ABCA1[J]. J Physiol Biochem, 2022, 78(3):653-666. doi:10.1007/s13105-022-00885-6.
[38]	JIANG H, TOSCANO J F, SONG S S, et al. Differential expression of circulating exosomal microRNAs in refractory intracranial atherosclerosis associated with antiangiogenesis[J]. Sci Rep, 2019, 9(1):19429. doi:10.1038/s41598-019-54542-y.
[39]	LI Y, DU L, MENG L, et al. High expression of CASP1 induces atherosclerosis[J]. Medicine(Baltimore), 2024, 103(16):e37616. doi:10.1097/MD.0000000000037616.
[40]	MAYR B, MÜLLER E E, SCHÄFER C, et al. Exercise-induced changes in miRNA expression in coronary artery disease[J]. Clin Chem Lab Med, 2021, 59(10):1719-1727. doi:10.1515/cclm-2021-0164.
[41]	SANTOS A S, CUNHA NETO E, FUKUI R T, et al. Increased expression of circulating microRNA 101-3p in type 1 diabetes patients:New insights into miRNA-regulated pathophysiological pathways for type 1 diabetes[J]. Front Immunol, 2019, 10:1637. doi:10.3389/fimmu.2019.01637.
[42]	蒋凯, 陈永顺. miR-101-3p通过MAPK信号通路保护心肌缺血再灌注损伤的机制研究[J]. 现代医学, 2022, 50(6):665-671.
	JIANG K, CHEN Y S. Mechanism of miR-101-3p protecting myocardial ischemia-reperfusion injury through MAPK signaling pathway[J]. Modern Medical Journal, 2022, 50(6):665-671. doi:10.3969/j.issn.1671-7562.2022.06.001.